Video

Dr. Burris on the Potential of PARP Inhibitors in TNBC

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with with triple-negative breast cancer (TNBC).

Oral PARP inhibitors taken once a day are being used to treat patients with TNBC, particularly those with BRCA mutations, such as inherited germline mutations or somatic mutations.

Some early results in the treatment of patients with ovarian cancer have been positive, says Burris, with PARP inhibitors approved in the maintenance setting and in later settings of ovarian cancer.

TNBC clinical trial results have been positive, as this subgroup's molecular genotype makes them sensitive to PARP inhibitors. However, more research needs to be done on how to give these inhibitors in neoadjuvant or later-line settings, says Burris.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc